Laurent Gauthier
Marseille, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Targeting BCMA in multiple myeloma with a trifunctional NK cell engager.
Journal: Cell reports. Medicine
Published: August 20, 2025
Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing.
Journal: Journal for immunotherapy of cancer
Published: March 17, 2025
A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma.
Journal: Science immunology
Published: November 15, 2024
Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities.
Journal: Experimental hematology & oncology
Published: July 16, 2024
New immune cell engagers for cancer immunotherapy.
Journal: Nature reviews. Immunology
Published: December 06, 2023
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.
Journal: Haematologica
Published: October 04, 2022
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Journal: Nature biotechnology
Published: August 10, 2022
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.
Journal: Open research Europe
Published: October 18, 2021
Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
Journal: Cancer immunology research
Published: October 07, 2021
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
Journal: European journal of immunology
Published: March 16, 2021
Last Updated: 09/26/2026